1138PFirst-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
ConclusionsICI given as second line treatment were associated with similar OS but significant prolonged duration of response. We showed a trend to better OS in the cohort of pts who received ICI in second line setting (22 months).Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | France Health | Immunotherapy | Legislation | Skin Cancer | Squamous Cell Carcinoma | Study